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Combination antiretroviral therapy (ART) as we know it
today has only been practiced in Africa in a significant
segment of people living with HIV (PLH) in the past 6
years. We have put behind us the litany of reasons
which were given as obstacles in the implementation of
ART in Africa. Today the majority of the 5.2 million
people on ART are from sub-Saharan Africa. Cohort
comparisons between resource-rich and resource-limited
settings have demonstrated similar immunologic and
virologic responses to ART. There is however a higher
mortality, of more than 4 times in the first 6 months of
ART in the developing world. There is therefore need to
address this early mortality to fully harness the benefits
of ART. Ecological data from a region in South Africa
has shown that tuberculosis rates have fallen by 50% in
the community in association with the widespread use
of ART. The benefits of ART extend to many other
spheres including reduction of perinatal infection and
improved socio-economic indices in children and adults.
There is also strong argument that the increased roll-
out of ART will impact maternal mortality, hence con-
tribute to the achievement of MDG5. Potential addi-
tional benefits of antiretroviral therapy in prevention are
emerging as exemplified by the positive outcome of
CAPRISA004; a study that showed a preventive role of
tenofovir gel of 39% in women in Durban, South Africa.
Other ARV-based microbicide studies and studies of
ART as pre-exposure prophylaxis will report soon and
may broaden the use and benefits of ART beyond thera-
peutics. The roll-out of ART in Africa is not without
challenges. Currently only 42% of PLH who qualify for
treatment are on therapy, moreover it is estimated that
10 million more will require ART when the new WHO
guidelines recommendation of ART initiation at a
threshold of 350 cells/mm
3 are considered.
Other recommendations including emphasis on diag-
nosing HIV early, the use of more expensive drugs in
first-line therapy, the emphasis on immunologic and vir-
ologic diagnosis of failure will require increased
resources. The availability of resources is threatened by
the world economic crisis and changing funding para-
digms. The challenge ahead is to mobilize resources to
enable use of ART in an efficient manner and in a way
that exploits the expanding role of ART in both HIV
therapy and prevention.
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